Targeted therapies for prostate cancer - Abstract

New therapies for prostate cancer have emerged over the past three years.

Nevertheless, none of these agents is curative, and unfortunately, patients often ultimately develop resistance to these agents. Therefore, the development of innovative and effective therapies that overcome these resistances is necessary. Unfortunately, the results of a phase III trial evaluating docetaxel in combination with targeted therapies demonstrated no difference in survival. Moreover, scarce data on the combination of a targeted therapy with new agents are currently available. New trials are investigating these possible combination treatments; the results of these (on-going) clinical studies are awaited.

Written by:
Petrioli R, Francini E, Fiaschi AI, Laera L, Roviello G.   Are you the author?
Medical Oncology Unit, University of Siena, Siena, Italy.

Reference: Cancer Invest. 2015 May 7. Epub ahead of print.
doi: 10.3109/07357907.2015.1033105


PubMed Abstract
PMID: 25951372

UroToday.com Prostate Cancer Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe